MA38991A1 - Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt - Google Patents

Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt

Info

Publication number
MA38991A1
MA38991A1 MA38991A MA38991A MA38991A1 MA 38991 A1 MA38991 A1 MA 38991A1 MA 38991 A MA38991 A MA 38991A MA 38991 A MA38991 A MA 38991A MA 38991 A1 MA38991 A1 MA 38991A1
Authority
MA
Morocco
Prior art keywords
urea derivatives
substituted indole
sglt inhibitors
glucopyranosyl substituted
glucopyranosyl
Prior art date
Application number
MA38991A
Other languages
English (en)
Other versions
MA38991B1 (fr
Inventor
Todd Fields
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA38991A1 publication Critical patent/MA38991A1/fr
Publication of MA38991B1 publication Critical patent/MA38991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/044—Pyrrole radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Cette invention concerne un composé de formule (i) : ou un sel pharmaceutiquement acceptable de celui-ci.
MA38991A 2013-11-01 2014-10-28 Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt MA38991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361898494P 2013-11-01 2013-11-01
PCT/US2014/062548 WO2015065956A1 (fr) 2013-11-01 2014-10-28 Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt

Publications (2)

Publication Number Publication Date
MA38991A1 true MA38991A1 (fr) 2017-11-30
MA38991B1 MA38991B1 (fr) 2018-09-28

Family

ID=51862614

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38991A MA38991B1 (fr) 2013-11-01 2014-10-28 Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt

Country Status (38)

Country Link
US (1) US9145437B2 (fr)
EP (1) EP3063162B1 (fr)
JP (1) JP6147429B2 (fr)
KR (1) KR101838826B1 (fr)
CN (1) CN105636972B (fr)
AP (1) AP2016009137A0 (fr)
AR (1) AR098134A1 (fr)
AU (1) AU2014342612B2 (fr)
BR (1) BR112016008704B1 (fr)
CA (1) CA2924516C (fr)
CL (1) CL2016000988A1 (fr)
CR (1) CR20160146A (fr)
CY (1) CY1119540T1 (fr)
DK (1) DK3063162T3 (fr)
DO (1) DOP2016000062A (fr)
EA (1) EA029516B1 (fr)
ES (1) ES2646125T3 (fr)
HR (1) HRP20171514T1 (fr)
HU (1) HUE034689T2 (fr)
IL (1) IL244896B (fr)
JO (1) JO3298B1 (fr)
LT (1) LT3063162T (fr)
MA (1) MA38991B1 (fr)
ME (1) ME02839B (fr)
MX (1) MX373441B (fr)
NO (1) NO3099623T3 (fr)
NZ (1) NZ717880A (fr)
PE (1) PE20160663A1 (fr)
PH (1) PH12016500809B1 (fr)
PL (1) PL3063162T3 (fr)
PT (1) PT3063162T (fr)
RS (1) RS56417B1 (fr)
SG (1) SG11201602950UA (fr)
SI (1) SI3063162T1 (fr)
TN (1) TN2016000125A1 (fr)
TW (1) TWI657093B (fr)
UA (1) UA117137C2 (fr)
WO (1) WO2015065956A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110128493B (zh) * 2018-02-08 2021-01-12 亚宝药业集团股份有限公司 吡喃糖取代杂环化合物的盐及其制备方法和用途
WO2024055932A1 (fr) * 2022-09-13 2024-03-21 亚宝药业集团股份有限公司 Composé azacyclique, composition pharmaceutique associée et utilisation s'y rapportant pour prévenir et/ou traiter une maladie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200501094B (en) * 2002-08-08 2006-10-25 Kissei Pharmaceutical Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
CN100413878C (zh) * 2002-08-23 2008-08-27 橘生药品工业株式会社 吡唑衍生物、含该衍生物的医药组合物、其医药用途及用于制备的中间体
JP5046370B2 (ja) * 2004-09-29 2012-10-10 キッセイ薬品工業株式会社 １−（β−Ｄ−グリコピラノシル）−３−置換含窒素ヘテロ環化合物、それを含有する医薬組成物及びその医薬用途
US7750145B2 (en) 2004-11-18 2010-07-06 Kissei Pharmaceutical Co., Ltd. 1-substituted-3-β-D-glucopyranosylated nitrogenous hetero-cyclic compounds and medicines containing the same
TWI418556B (zh) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp 吲哚衍生物
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) * 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物

Also Published As

Publication number Publication date
MX373441B (es) 2020-05-20
PL3063162T3 (pl) 2018-01-31
BR112016008704B1 (pt) 2022-11-29
CN105636972A (zh) 2016-06-01
WO2015065956A1 (fr) 2015-05-07
CR20160146A (es) 2016-05-30
IL244896A0 (en) 2016-05-31
SG11201602950UA (en) 2016-05-30
PE20160663A1 (es) 2016-07-09
HUE034689T2 (hu) 2018-02-28
TWI657093B (zh) 2019-04-21
US20150126469A1 (en) 2015-05-07
LT3063162T (lt) 2017-10-25
JP2016535032A (ja) 2016-11-10
HRP20171514T1 (hr) 2017-11-17
CA2924516A1 (fr) 2015-05-07
NO3099623T3 (fr) 2018-04-21
JO3298B1 (ar) 2018-09-16
CA2924516C (fr) 2019-09-10
EP3063162A1 (fr) 2016-09-07
MA38991B1 (fr) 2018-09-28
DK3063162T3 (en) 2017-10-02
MX2016005428A (es) 2016-08-11
CL2016000988A1 (es) 2016-11-11
UA117137C2 (uk) 2018-06-25
KR20160060138A (ko) 2016-05-27
ME02839B (fr) 2018-01-20
KR101838826B1 (ko) 2018-03-14
AR098134A1 (es) 2016-05-04
AU2014342612B2 (en) 2016-09-29
PT3063162T (pt) 2017-11-14
IL244896B (en) 2019-02-28
ES2646125T3 (es) 2017-12-12
AP2016009137A0 (en) 2016-04-30
PH12016500809A1 (en) 2016-06-13
EP3063162B1 (fr) 2017-08-16
HK1222661A1 (en) 2017-07-07
EA201690593A1 (ru) 2016-08-31
PH12016500809B1 (en) 2019-04-26
CN105636972B (zh) 2018-05-22
RS56417B1 (sr) 2018-01-31
DOP2016000062A (es) 2016-03-31
BR112016008704A8 (pt) 2020-03-17
SI3063162T1 (sl) 2017-10-30
JP6147429B2 (ja) 2017-06-14
NZ717880A (en) 2017-12-22
CY1119540T1 (el) 2018-03-07
EA029516B1 (ru) 2018-04-30
TN2016000125A1 (en) 2017-10-06
TW201609784A (zh) 2016-03-16
AU2014342612A1 (en) 2016-03-31
US9145437B2 (en) 2015-09-29

Similar Documents

Publication Publication Date Title
EA201592199A1 (ru) Производные бипиразола в качестве ингибиторов jak
MD4684B1 (ro) Formulări pe bază de imidazopirazine în calitate de inhibitori SYK
PH12018500041A1 (en) Substituted aza compoounds as irak-4 inhibitors
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
EA201990833A1 (ru) Соединение пиридина
MX391812B (es) Agonista fxr derivado de esteroides.
EA201791563A1 (ru) Замещенные нуклеозидные производные, полезные в качестве агентов против рака
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
BR112015032693A2 (pt) inibidores de bromodomínio
BR112017019286A2 (pt) composto de fórmula (i) ou um sal farmaceuticamente aceitável deste
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
NZ716840A (en) Combination formulation of two antiviral compounds
BR112015022643A2 (pt) inibidores diidro-pirrolpiridinona
MA38583B1 (fr) Dérivés de dolastatine 10 et d'auristatines
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
MD4659B1 (ro) Polimorf al inhibitorilor SYK
EA201591301A1 (ru) Новые пиримидиновые и пиридиновые соединения и их применение
EA201600434A1 (ru) Применение производных бензимидазолпролина
MA40250A (fr) Dérivés de quinolizinone utilisés comme inhibiteurs de pi3k
MX2018008307A (es) Derivado de ascoclorina y uso del mismo como activador de proteina cinasa activada por adenosin monofosfato (ampk).
MA50093B1 (fr) Composé pentacyclique
JOP20170164A1 (ar) مشتق ترايازولو بيرازينون مفيد كمثبط لـ pde1 بشري
EA201600002A1 (ru) Производные пролекарства замещенных триазолопиридинов
MA38991B1 (fr) Dérivés d'indole-urée substitués par un glucopyranosyle et leur utilisation à titre d'inhibiteurs de sglt
MX375934B (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.